Carcinomas of the Oral Cavity
Histopathology Reporting Guide

<table>
<thead>
<tr>
<th>Family/Last name</th>
<th>Date of birth</th>
<th>DD – MM – YYYY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Given name(s)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient identifiers</th>
<th>Date of request</th>
<th>DD – MM – YYYY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Elements in **black text** are CORE. Elements in **grey text** are NON-CORE. |

### PRIOR NEOADJUVANT THERAPY (Note 1)
- Information not provided
- Not administered
- Administered, specify type
  - Chemotherapy
  - Radiotherapy
  - Targeted therapy, specify if available
  - Immunotherapy, specify if available

### OPERATIVE PROCEDURE (select all that apply) (Note 2)
- Not specified
- Biopsy (excisional, incisional), specify
- Resection, specify
- Glossectomy, specify
- Buccal mucosa, specify
- Lip, specify
- Mandibulectomy, specify
- Maxillectomy, specify
- Palatectomy, specify
- Neck (lymph node) dissection*, specify
- Other, specify

* If a neck dissection is submitted, then a separate dataset is used to record the information.

### SPECIMENS SUBMITTED (select all that apply) (Note 3)
- Not specified
- Buccal mucosa
- Buccal vestibule
- Retromolar trigone
- Alveolar process
- Mandible
- Maxilla
- Lip
- Tongue
- Gingiva
- Floor of mouth
- Hard palate
- Other, specify

### TUMOUR SITE (select all that apply) (Note 3)
- Not specified
- Vermilion border upper lip
  - Left
  - Midline
  - Right
  - Laterality not specified
- Vermilion border lower lip
  - Left
  - Midline
  - Right
  - Laterality not specified
- Mucosa of upper lip
  - Left
  - Midline
  - Right
  - Laterality not specified
- Mucosa of lower lip
  - Left
  - Midline
  - Right
  - Laterality not specified
- Commissure of lip
  - Left
  - Midline
  - Right
  - Laterality not specified
- Lateral border of tongue
  - Left
  - Midline
  - Right
  - Laterality not specified
- Ventral surface of tongue, not otherwise specified (NOS)
  - Left
  - Midline
  - Right
  - Laterality not specified
- Dorsal surface of tongue, NOS
  - Left
  - Midline
  - Right
  - Laterality not specified
- Anterior two-thirds of tongue, NOS
  - Left
  - Midline
  - Right
  - Laterality not specified
- Upper gingiva (gum)
  - Left
  - Midline
  - Right
  - Laterality not specified
- Lower gingiva (gum)
  - Left
  - Midline
  - Right
  - Laterality not specified
TUMOUR FOCALITY (Note 4)
- Unifocal
- Bilateral
- Multifocal, specify number of tumours in specimen
- Cannot be assessed, specify

MACROSCOPIC TUMOUR DIMENSIONS (Note 5)
- No macroscopically visible tumour
- Cannot be assessed, specify

Maximum tumour dimension (largest tumour)

MICROSCOPIC TUMOUR DIMENSIONS (select all that apply) (Note 6)
- Cannot be determined/surgical resection margins involved

Maximum tumour dimension (largest tumour)

Additional dimensions (largest tumour)

Maximum depth of invasion (to reconstructed basement membrane)

HISTOLOGICAL TUMOUR TYPE (select all that apply) (Note 7)
(Value list from the World Health Organisation Classification of Head and Neck Tumours (2017))

- Squamous cell carcinoma
  - Squamous cell carcinoma, conventional type
  - Basaloid squamous cell carcinoma
  - Papillary squamous cell carcinoma
  - Verrucous carcinoma
  - Spindle (sarcomatoid) squamous cell carcinoma
  - Adenosquamous cell carcinoma
  - Acantholytic squamous cell carcinoma
  - Carcinoma cuniculatum
  - Lymphoepithelial squamous cell carcinoma
  - Other, specify

- Minor salivary gland tumour, specify type

- Neuroendocrine carcinoma, specify type

- Other, specify type

HISTOLOGICAL TUMOUR GRADE (Note 8)
- Not applicable
- GX: Cannot be assessed
- G1: Well differentiated
- G2: Moderately differentiated
- G3: Poorly differentiated
- Other, specify

DEPTH OF INVASION (Note 9)
(Resection specimens only, not applicable to biopsies)
- ≤5 mm depth of invasion
- >5 mm and ≤10 mm depth of invasion
- >10 mm depth of invasion
- Cannot be assessed, specify
**RESPONSE TO NEOADJUVANT THERAPY** (Note 11)
- No prior treatment
- Incomplete response
- Complete response
- Response cannot be assessed, explain reasons

**PATTERN OF INVASIVE FRONT** (Note 10)
- Resection specimens only, not applicable to biopsies
  - Cohesive
  - Non-cohesive
  - Widely dispersed

**BONE INVASION** (Note 12)
- Not identified
- Present
  - Erosive (cortical)
  - Infiltrative (medullary involvement)
- Indeterminate, specify

**PERINEURAL INVASION** (Note 13)
- Not identified
- Present
  - Nerve size, if known: mm
- Indeterminate, specify

**LYMPHOVASCULAR INVASION** (Note 14)
- Not identified
- Present
- Indeterminate, specify

**MARGIN STATUS** (Note 15)
**Invasive carcinoma**
- Involved
  - Specify margin(s), if possible
- Not involved
  - Distance of tumour from closest margin: mm
  - Specify closest margin, if possible
  - Distance not assessable

**BONE INVASION** (Note 12)
- Not identified
- Present
  - Erosive (cortical)
  - Infiltrative (medullary involvement)
- Indeterminate, specify

**PERINEURAL INVASION** (Note 13)
- Not identified
- Present
  - Nerve size, if known: mm
- Indeterminate, specify

**LYMPHOVASCULAR INVASION** (Note 14)
- Not identified
- Present
- Indeterminate, specify

**MARGIN STATUS** (Note 15)
**Invasive carcinoma**
- Involved
  - Specify margin(s), if possible
- Not involved
  - Distance of tumour from closest margin: mm
  - Specify closest margin, if possible
  - Distance not assessable

**CARCINOMA IN SITU/HIGH-GRADE DYSPLASIA**
- Involved
  - Specify margin(s), if possible
- Not involved
  - Distance of tumour from closest margin: mm
  - Specify closest margin, if possible
  - Distance not assessable

**COEXISTENT PATHOLOGY** (select all that apply) (Note 16)
- None identified
- Proliferative verrucous leukoplakia
- Fungal infection
- Dysplasia
  - Not identified
  - Present, specify grade
- HPV positive dysplasia
  - Not identified
  - Present
- Submucous fibrosis
  - Not identified
  - Present
- Inflammation
  - Not identified
  - Present
- Other, specify

**ANCILLARY STUDIES** (Note 17)
- Not performed
- Performed, specify
PATHOLOGICAL STAGING (UICC TNM 8th edition)** (Note 18)

**TNM Descriptors** (only if applicable) (select all that apply)
- m - multiple primary tumours
- r - recurrent
- y - post-therapy

**Primary tumour (pT)**
- TX Primary tumour cannot be assessed
- Tis Carcinoma in situ
- T1 Tumour 2 cm or less in greatest dimension and 5 mm or less depth of invasion****
- T2 Tumour 2 cm or less in greatest dimension and more than 5 mm but no more than 10 mm depth of invasion or Tumour more than 2 cm but not more than 4 cm in greatest dimension and depth of invasion no more than 10 mm
- T3 Tumour more than 4 cm in greatest dimension or more than 10 mm depth of invasion
- T4a (Lip) Tumour invades through cortical bone, inferior alveolar nerve, floor or mouth, or skin (the chin or the nose)
- T4a (Oral cavity) Tumour invades through cortical bone of mandible or maxillary sinus, or invades the skin of the face
- T4b (Lip and oral cavity) Tumour invades masticator space, pterygoid plates, or skull base, or encases internal carotid artery

*** Note that the results of lymph node/neck dissection are derived from a separate dataset.

**** Superficial erosion alone of bone/tooth socket by gingival primary is not sufficient to classify a Tumour as T4a.

Scope

The dataset has been developed for the reporting of resection and biopsy specimens of invasive carcinomas of the oral cavity, including lip and tongue. Mucosal melanoma, lymphomas and sarcomas are not included. In addition, neck dissections and nodal excisions are dealt with in a separate dataset, and this dataset should be used in conjunction, where applicable.

Note 1 – Prior neoadjuvant therapy (Non-core)

Reason/Evidentiary Support

There is no agreed upon system for grading tumour regression in oral squamous cell carcinoma that has been treated with neoadjuvant therapy. However, a history of previous radiotherapy and/or chemotherapy should be included as histologic changes related to the therapy such as necrosis may affect interpretation of the tumour.

Note 2 – Operative procedure (Core)

Reason/Evidentiary Support

Important to correlate the type of procedure (excisional biopsy or resection) with the material received for patient safety. Site-specific designations are required for accurate staging and for cancer registration. Modification of the resection, e.g. partial, total should be described. For example: hemi-glossectomy, partial glossectomy; hemi-mandibulectomy, segmental (partial) mandibulectomy; partial maxillectomy, total maxillectomy; selective neck dissection, modified neck dissection.1,2

Note 3 – Specimens submitted (Core) and Tumour type (Core)

Reason/Evidentiary Support

The anatomy and surgical interventions of the oral cavity are complex and it is important to ensure accurate and precise communication between the pathologists and the treating and diagnostic team with respect to exact anatomic site of involvement, tumour laterality and specific operative procedures.3-5

The protocol applies to all carcinomas arising at these sites (see Figure 1). For large cancers that involve more than one site, the primary site of involvement should be recorded.
Mucosal Lip. The lip begins at the junction of the vermilion border with the skin and includes only the vermilion surface or that portion of the lip that meets the opposing lip.

Buccal Mucosa (Inner Cheek). Refers to the mucous membrane lining of the inner surface of the cheeks and lips of contact of the opposing lips to the line of attachment of mucosa of the upper and lower alveolar ridge and pterygomandibular raphe.

Lower Alveolar Ridge. This refers to the mucosa overlying the alveolar process of the mandible, which extends from the line of attachment of mucosa in the buccal vestibule to the line of free mucosa of the floor of the mouth. Posteriorly it extends to the ascending ramus of the mandible.

Upper Alveolar Ridge. This refers to the mucosa overlying the alveolar process of the maxilla, which extends from the line of attachment of mucosa in the upper gingival buccal vestibule to the junction of the hard palate. The posterior margin is the upper end of the pterygopalatine arch.

Floor of the Mouth. This is a semilunar space over the mylohyoid and hypoglossus muscles, extending from the inner surface of the lower alveolar ridge to the undersurface of the tongue. The posterior boundary is the base of the anterior pillar of the tonsil. It is divided into two sides of the submaxillary and sublingual salivary glands.

Hard Palate. This is the semilunar area between the upper alveolar ridge and the mucous membrane covering the palatine process of the maxillary palatine bones. It extends from the inner surface of the superior alveolar ridge to the posterior edge of the palatine bone.

Anterior Two-Thirds of the Tongue (Oral Tongue). This is the freely mobile portion of the tongue that extends anteriorly from the line of circumvallate papillae to the undersurface (ventral) of the tongue at the junction of the floor of the mouth. It includes the tip of tongue, lateral borders, dorsal surface and ventral tongue.

Retromolar trigone. A triangular shaped region extending distal from the mandibular third molar as the base and attaches to the hamulus of the medial pterygoid process of the sphenoid bone as the apex.

‘Not specified’ should be used rarely and only after good effort has been employed to obtain the requisite information.
Figure 1. Anatomic sites and subsites for lip and oral cavity

Note 4 – Tumour focality (Non-core)

Reason/Evidentiary Support

True multifocal or synchronous oral cavity carcinomas are rare. Patients with oral squamous cell carcinomas have a high incidence (2-3%) of developing a second primary lesion however these are usually metachronous lesions. The theory of field cancerization whereby contiguous genetically altered areas of mucosa lead to the development of neoplasms have been supported by studies evaluating clonality and other molecular markers. Proliferative verrucous leukoplakia has the propensity of developing multifocal tumours. It is rare to have multiple tumours disconnected but not uncommon to have more than one squamous cell carcinoma connected via dysplasia. The location, proximity to dysplastic epithelium, depth and nodal status remain important. Tumour focality seems to be a standard not just for staging and pathology but for clinical trials and treatment considerations. 6-9
Note 5 – Macroscopic tumour dimensions (Core)

Reason/Evidentiary Support

The macroscopic tumour dimension is an important component in pathologic staging. Acknowledgement is made of fixation and processing distortion on measurements which may cause tumour shrinkage. Occasionally, microscopic tumour extent may exceed macroscopic measurements and tumour size will need to be measured microscopically in these cases.

Note 6 – Microscopic tumour dimensions (Core)

Reason/Evidentiary Support

The microscopic tumour dimensions should be the primary dimension used for pathologic staging since it is the only staging system that accurately depicts three dimensional measurements and actually differentiates what clinically (phenotypically) appears to be tumour from what is actual invasion (not dysplasia or inflammation) microscopically. The maximum depth of invasion should be recorded as core and the discussion should include how/why depth of invasion is different than tumour thickness.

Note 7 – Histological tumour type (Core)

Reason/Evidentiary Support

The major histologic tumour types of squamous cell carcinoma as recognized by the World Health Organisation (WHO) classification are squamous cell carcinoma, conventional type, basaloid, papillary, spindle, adenosquamous, acantholytic, lymphoepithelial, verrucous carcinoma and carcinoma cuniculatum. Hybrid lesions such as verrucous carcinoma and squamous cell carcinoma exist and should be recognized as it may affect prognosis. Subtypes should be assigned for both prognosis and cancer registry. Salivary carcinoma histologic type essentially defines its biologic behaviour and thus influences prognosis, patterns of recurrence and thus clinical management. Some carcinoma types (i.e. basal cell adenocarcinoma, conventional acinic cell carcinoma) are more indolent with locoregional recurrence but low nodal and distant metastatic rates.

The major histologic salivary gland carcinomas of minor salivary glands as recognized by the WHO classification are acinic cell carcinoma, adenoid cystic carcinoma, adenocarcinoma NOS, (mammary analogue) secretory carcinoma, cystadenocarcinoma, epithelial-myoepithelial carcinoma, mucoepidermoid carcinoma (low, intermediate and high grade), polymorphous adenocarcinoma
(low, intermediate and high grade), (hyalinizing) clear cell carcinoma, intraductal carcinoma, carcinosarcoma, myoepithelial carcinoma, oncocytic carcinoma

Carcinoma ex pleomorphic adenoma is subclassified by type and extent of invasion, the latter including minimally invasive, invasive and intracapsular (non-invasive) cancers. The definition for minimally invasive carcinomas varies, ranging from 1.5 mm to 6 mm. Invasive carcinomas extend beyond 6 mm; non-invasive cancers are completely confined to within the capsule without evidence of penetration into extracapsular tissue. Prior to diagnosing a non-invasive carcinoma ex pleomorphic adenoma, sectioning of the entire lesion for histologic evaluation is recommended to exclude the presence of invasive growth. Prognosis has been linked to degree of invasion with non-invasive and minimally invasive cancers apparently having a better prognosis than invasive cancers.28,29

### WHO classification of tumours of the oral cavity and mobile tongue30

<table>
<thead>
<tr>
<th>Descriptor</th>
<th>ICD-O codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epithelial tumours and lesions</td>
<td></td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>8070/3</td>
</tr>
<tr>
<td>Oral epithelial dysplasia</td>
<td></td>
</tr>
<tr>
<td>Low grade</td>
<td>8077/0</td>
</tr>
<tr>
<td>High grade</td>
<td>8077/2</td>
</tr>
</tbody>
</table>

a The morphology codes are from the International Classification of Diseases for Oncology (ICD-O). Behaviour is coded /0 for benign tumours; /1 for unspecified, borderline, or uncertain behaviour; /2 for carcinoma in situ and grade III intraepithelial neoplasia; and /3 for malignant tumours

© WHO/International Agency for Research on Cancer (IARC). Reproduced with permission

↑ Back

### Note 8 – Histological tumour grade (Core)

**Reason/Evidentiary Support**

Based on the WHO classifications, three histologic grades of squamous cell carcinoma, conventional type are used: well, moderately or poorly differentiated. The most aggressive or highest grade should be recorded if the tumour has a varied histology. Grading requires the assessment of keratinization, mitotic activity, cellular and nuclear pleomorphism, pattern of invasion and host response.1,31-34 Squamous cell carcinoma subtypes such as verrucous carcinoma, basaloid squamous cell carcinoma, papillary squamous cell carcinoma are not graded.
**Note 9 – Depth of invasion** (Core)

**Reason/Evidentiary Support**

Depth of invasion (DOI) in oral cavity squamous cell carcinoma, particularly of the tongue, has been identified as an important prognostic indicator. DOI is not synonymous with tumour thickness. In the recent American Joint Committee on Cancer (AJCC) the tumour stage (T) has been changed to reflect the importance of DOI. DOI increases T by 1 step for every 5 mm, whereby T1 is tumour ≤ 2 cm and DOI ≤ 5 mm, T2 is tumour ≤ 2 cm and DOI > 5 mm and ≤ 10 mm or tumour > 2 cm but ≤ 4 cm and ≤ 10 mm DOI and T3 is tumour > 4 cm or any tumour > 10 mm DOI. DOI measures the invasiveness of the carcinoma. To measure DOI, the basement membrane is identified and an imaginary line is drawn across the tumour. A vertical or “plumb line” extends to the deepest part of the tumour which represents the DOI. It is important to note that DOI is not synonymous with tumour thickness. An exophytic tumour (Figure 2A) may be thicker than an ulcerative tumour (Figure 2B), but the DOI of the ulcerative lesion may be greater.15-38

![Diagram showing Measuring depth of invasion of an exophytic tumour](image-url)
Note 10 – Pattern of Invasive front (Core)

Reason/Evidentiary Support

The pattern of invasion in oral squamous cell carcinoma has proven prognostic value and should be reported as cohesive or non-cohesive (Figure 3). It is important to evaluate the most complex area of tumour-stroma interface (“worst” area) and consequently assessment should only be made on resection specimens. Cohesive invasion is defined as broad sheets of cancer cells and/or tumour nests >15 cells across. Non-cohesive invasion shows a spectrum of appearances that includes narrow strands, small groups of <15 tumour cells and single infiltrating tumour cells. For stage T1/T2 oral squamous cell carcinoma, particularly those arising in the tongue there is evidence that tumour satellites localized ≥ 1 mm away from the main tumour or nearest satellite (worst pattern of invasion WPOI-5) is a valid adverse prognostic factor.
**Note 11 – Response to neoadjuvant therapy (Non-core)**

**Reason/Evidentiary Support**

There is no agreed system for grading tumour regression in oral squamous cell carcinoma that has been treated with neoadjuvant therapy. Specific pathologic changes in response to neoadjuvant chemotherapy, although well described in other organ systems is lacking in oral cavity cancer. These changes include necrosis, fibrosis, cytologic atypia and inflammation. As the field of neoadjuvant therapy for oral cavity cancer evolves histologic changes important for treating clinicians may be better elucidated.

**Note 12 – Bone invasion (Core)**

**Reason/Evidentiary Support**

Infiltrative bone involvement by squamous cell carcinoma correlates with a worse prognosis. Bone invasion may be a macroscopic feature, however sampling through the involved bone for histologic examination should be performed to obtain histologic evidence. The presence of bone invasion affects tumour staging and patients with bone invasion often have a worse prognosis. If bone is resected, then bone margins should be recorded.\(^{14}\)
Note 13 – Perineural invasion (Core and non-core)

Reason/Evidentiary Support

Perineural invasion is associated with a worse prognosis, regardless of nerve size and should be recorded. The presence or absence of perineural and/or endoneural/intraneural invasion may impact subsequent therapy and prognosis.1,32,40-42

Note 14 – Lymphovascular invasion (Core)

Reason/Evidentiary Support

There is a need to distinguish between intravascular tumour embolization and retraction artefact. Positive vascular invasion should be reported only when tumour emboli are identified within endothelial lined spaces. No distinction between venous channels and small lymphatics is required.34,43

Note 15 – Margin status (Core)

Reason/Evidentiary Support

All surgical margins should be measured in millimetres histologically for both mucosal and deep margins. In the comments section, acknowledgement should be made how the surgical margin was measured, for example if the margin was submitted in situ at the time of the operative procedure rather than from the surgical specimen. The presence of high grade dysplasia/carcinoma in situ at the margin is associated with an increased risk of local recurrence and this should be recorded. The definition of a “close” margin is not standardized but in the oral cavity from a surgical point of view >5 mm is clear and 1-5 mm is close while <1 mm is involved. Acknowledgement is made of fixation and processing distortion on measurements which may cause tissue shrinkage including the surgical margin.11 Any bone resection margins should be identified and comment on the presence or absence of carcinoma at these margins should be provided.1,31,32,38,44-47 Dysplastic changes include abnormal cellular organization, increased mitotic activity, and nuclear enlargement with pleomorphism. Although terminology varies, dysplasia limited to the lower one-third of the epithelium is generally referred to as mild dysplasia or low-grade dysplasia, dysplasia limited to the lower two-thirds as moderate dysplasia and dysplasia involving the full thickness as severe dysplasia/carcinoma in situ. The term high grade dysplasia includes both moderate dysplasia and severe dysplasia.

Reporting of surgical margins for carcinomas of the minor salivary glands should follow those used for squamous cell carcinoma of oral cavity.
Note 16 – Coexistent pathology (Non-core)

Reason/Evidentiary Support

The most common sites of dysplasia with the highest risk of malignant transformation are lateral and ventral tongue, floor of mouth, and lower lip. Dysplastic changes include abnormal cellular organization, increased mitotic activity including abnormal forms, and nuclear enlargement with pleomorphism. Although terminology varies, dysplasia limited to the lower one-third of the epithelium is generally referred to as mild dysplasia (low-grade dysplasia), dysplasia limited to the lower two-thirds as moderate dysplasia and dysplasia involving the full thickness as severe dysplasia/carcinoma in situ.\(^{48}\) However, when moderate dysplasia has marked cytologic atypia, then often the lesion will be upgraded to severe dysplasia. The term high-grade dysplasia includes moderate and severe dysplasia and carcinoma in situ. A recently described subset of oral dysplasia is positive for high-risk HPV. The epithelium exhibits full-thickness dysplastic changes with karyorrhexis and apoptosis and the cells are strongly positive for p16 by immunohistochemistry.\(^{49}\)

Proliferative verrucous leukoplakia (PVL) is a distinct form of oral precancer of unknown etiology with a multifocal presentation and a progressive course with high recurrence rates and malignant transformation in as many as 70% of cases.\(^{50,51}\) This diagnosis requires adequate clinical information. Subepithelial fibrosis is a characteristic of oral submucous fibrosis and increased fibrosis is associated with an increased risk of epithelial dysplasia.\(^{52}\) Some inherited genetic mutations are associated with a higher risk of oral cancer development including Fanconi anemia, Li-Fraumeni syndrome and dyskeratosis congenita.\(^{52}\) Care must be taken to rule out reactive atypia which can be seen in epithelium adjacent to ulcers and with fungal infections.

↑ Back

Note 17 – Ancillary studies (Non-core)

Reason/Evidentiary Support

In most cases, further studies are not required for the diagnosis. Epithelial immunohistochemical markers may be required for poorly differentiated or spindle cell carcinoma including AE1/AE3, CK5/6, p63 and p40. Lymphoepithelial squamous cell carcinoma in the oral cavity is rare and although not all cases are EBV-positive, Epstein-Barr virus (EBV)-encoded small RNAs (EBERs) studies are indicated. There is currently no role for routine HPV high risk type testing in oral squamous cell carcinoma.\(^{53-57}\)

↑ Back
Note 18 – Pathological staging (Core)

Reason/Evidentiary Support

By AJCC/Union for International Cancer Control (UICC) convention, the designation “T” refers to a primary tumour that has not been previously treated. Both staging systems integrates depth of invasion (DOI) into the T categories. Similar to skin malignancies, DOI is significantly associated with disease-free survival.\textsuperscript{58} Per the AJCC 8th edition, specific instructions are given to measure DOI.\textsuperscript{10} To measure DOI, the basement membrane is identified and an imaginary line is drawn across the tumour. A vertical or “plumb line” extends to the deepest part of the tumour which represents the DOI. It is important to note that DOI is not synonymous with tumour thickness. An exophytic tumour may be thicker than an ulcerative tumour, but the DOI of the ulcerative lesion may be greater. An important point to highlight is that the UICC 8th edition does not specify how DOI should be measured.\textsuperscript{59} Superficial erosion alone of bone/tooth socket by primary gingival tumour is not sufficient to classify a tumour as T4a which requires invasion into medullary bone.

Extranodal extension (ENE) is associated with adverse outcomes. ENE is defined as microscopic or macroscopic. Microscopic ENE is defined as ≤ 0.2 cm whereas macroscopic ENE is defined as ENE clinically apparent at time of dissection or microscopic tumour extension >0.2 cm beyond the lymph node capsule.

References


